The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) remains a very challenging malignancy with late presentation, metastatic potential, chemoresistance, and poor prognosis. Therefore, there is an urgent need for novel diagnostic and prognostic biomarkers. miRNAs are small noncoding RNAs that regulate the expres...

Full description

Saved in:
Bibliographic Details
Published inTherapeutics and clinical risk management Vol. 14; pp. 179 - 187
Main Authors Ren, Le, Yu, Yue
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2018
Taylor & Francis Ltd
Dove Medical Press
Subjects
Accuracy
Adenocarcinoma
Antigens
Biological markers
Biomarkers
Cancer metastasis
Cell growth
Chemoresistance
Diagnosis
Genes
Medical diagnosis
Medical prognosis
Micro-RNA
MicroRNA
MicroRNAs
Novels
Pancreatic cancer
Pancreatic ductal adenocarcinoma
Prognosis
Review
diagnosis
miRNA
chemoresistance
prognosis
pancreatic ductal adenocarcinoma
Online AccessGet full text

Cover

More Information
Summary:Pancreatic ductal adenocarcinoma (PDAC) remains a very challenging malignancy with late presentation, metastatic potential, chemoresistance, and poor prognosis. Therefore, there is an urgent need for novel diagnostic and prognostic biomarkers. miRNAs are small noncoding RNAs that regulate the expression of multitude number of genes. Aberrant expression of miRNAs has been linked to the development of various malignancies, including PDAC. A series of miRNAs have been defined as holding promise for early diagnostics, as indicators of therapy resistance, and even as markers for prognosis in PDAC patients. In this review, we summarize the current knowledge on the role of miRNAs in diagnosis, chemoresistance, and prognosis in PDAC patients.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1176-6336
1178-203X
1178-203X
DOI:10.2147/TCRM.S154226